Concurrent gemcitabine+S-1 neoadjuvant chemotherapy contributes to the improved survival of patients with small borderline-resectable pancreatic cancer tumors.
about
Superior mesenteric artery margin in pancreaticoduodenectomy for pancreatic adenocarcinomaA novel preoperative predictor of pancreatic fistula using computed tomography after distal pancreatectomy with staple closure.Meta-analysis comparing upfront surgery with neoadjuvant treatment in patients with resectable or borderline resectable pancreatic cancer.Subgroup analysis reveals molecular heterogeneity and provides potential precise treatment for pancreatic cancers
P2860
Concurrent gemcitabine+S-1 neoadjuvant chemotherapy contributes to the improved survival of patients with small borderline-resectable pancreatic cancer tumors.
description
2016 nî lūn-bûn
@nan
2016年の論文
@ja
2016年学术文章
@wuu
2016年学术文章
@zh-cn
2016年学术文章
@zh-hans
2016年学术文章
@zh-my
2016年学术文章
@zh-sg
2016年學術文章
@yue
2016年學術文章
@zh
2016年學術文章
@zh-hant
name
Concurrent gemcitabine+S-1 neo ...... able pancreatic cancer tumors.
@en
type
label
Concurrent gemcitabine+S-1 neo ...... able pancreatic cancer tumors.
@en
prefLabel
Concurrent gemcitabine+S-1 neo ...... able pancreatic cancer tumors.
@en
P2093
P2860
P1433
P1476
Concurrent gemcitabine+S-1 neo ...... able pancreatic cancer tumors.
@en
P2093
Asahi Sato
Kenzo Nakano
Kyoichi Takaori
Shinji Uemoto
Takayuki Anazawa
Tatsuo Ito
Toshihiko Masui
Yoshiya Kawaguchi
P2860
P304
P356
10.1007/S00595-016-1310-Z
P577
2016-02-09T00:00:00Z